Morgan Stanley Allakos Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Allakos Inc. stock. As of the latest transaction made, Morgan Stanley holds 361,812 shares of ALLK stock, worth $108,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares

361,812

Previous 996,353 63.69%

Holding current value

$108,543

Previous $647,000 32.46%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.62 - $1.5 $393,415 - $951,811	-634,541 Reduced 63.69%	361,812 $437,000
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.92 $420,238 - $715,962	-778,220 Reduced 43.85%	996,353 $647,000
Q2 2024 Oct 17, 2024	SELL	$1.0 - $1.45 $778,085 - $1.13 Million	-778,085 Reduced 30.48%	1,774,573 $1.77 Million
Q2 2024 Aug 14, 2024	SELL	$1.0 - $1.45 $778,085 - $1.13 Million	-778,085 Reduced 30.48%	1,774,573 $1.77 Million
Q1 2024 Oct 17, 2024	BUY	$1.02 - $3.23 $793,646 - $2.51 Million	778,085 Added 43.85%	2,552,658 $3.22 Million
Q1 2024 Aug 16, 2024	SELL	$1.02 - $3.23 $482,063 - $1.53 Million	-472,611 Reduced 15.62%	2,552,658 $3.22 Million
Q1 2024 May 15, 2024	SELL	$1.02 - $3.23 $482,063 - $1.53 Million	-472,611 Reduced 15.62%	2,552,658 $3.22 Million
Q4 2023 Aug 16, 2024	BUY	$1.72 - $3.18 $2.15 Million - $3.98 Million	1,250,696 Added 70.48%	3,025,269 $8.26 Million
Q4 2023 Feb 13, 2024	BUY	$1.72 - $3.18 $4.13 Million - $7.64 Million	2,402,938 Added 386.12%	3,025,269 $8.26 Million
Q3 2023 Nov 15, 2023	BUY	$2.13 - $5.55 $598,542 - $1.56 Million	281,006 Added 82.33%	622,331 $1.41 Million
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $1.79 Million - $2.61 Million	-496,296 Reduced 59.25%	341,325 $1.49 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $1.91 Million - $3.68 Million	445,321 Added 113.52%	837,621 $3.73 Million
Q4 2022 Feb 14, 2023	SELL	$5.66 - $8.42 $534,168 - $794,645	-94,376 Reduced 19.39%	392,300 $3.3 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $2.47 Million - $5.01 Million	-818,216 Reduced 62.7%	486,676 $2.98 Million
Q2 2022 Oct 27, 2022	BUY	$2.6 - $6.14 $73,408 - $173,356	28,234 Added 2.21%	1,304,892 $4.09 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $73,408 - $173,356	28,234 Added 2.21%	1,304,892 $4.09 Million
Q1 2022 Oct 27, 2022	SELL	$5.08 - $9.81 $143,428 - $276,975	-28,234 Reduced 2.16%	1,276,658 $7.28 Million
Q1 2022 May 13, 2022	BUY	$5.08 - $9.81 $1.95 Million - $3.77 Million	384,725 Added 43.13%	1,276,658 $7.28 Million
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $7.45 Million - $97.5 Million	871,050 Added 4171.1%	891,933 $8.73 Million
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $1.6 Million - $2.31 Million	20,883 New	20,883 $2.21 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

68.8M

Call Options Held

20.9K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $25.4M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account